The patent specifically covers the company’s RX-8243 which is currently in pre-clinical development.
According to the company, RX-8243 has demonstrated potent anti-tumor properties in many cancer cell lines, besides paclitaxel-resistant human colorectal xenograft models.
The drug candidate also showed cytotoxic effect when combined with other cancer drugs against human cancer cells.
Rexahn president Rick Soni said the US patent marks an important step in the development of RX-8243.